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SUMMARY 
 
 
A range of pharmaceuticals has been detected in soils, surface waters and 
groundwaters across the world. While the reported concentrations are generally low 
(i.e. sub µg l-1 in surface waters), the substances have been observed throughout the 
year across a variety of hydrological, climatic and land-use settings. As a result, 
questions have been raised over the potential for pharmaceuticals in surface waters 
to enter drinking water supplies and to affect consumers. 
 
In a previous Drinking Water Inspectorate (DWI) funded study, results from a simple 
exposure model were used alongside information on therapeutic doses of 
pharmaceuticals to identify pharmaceuticals that are likely to be of most concern in 
UK drinking water sources.  However, this previous study was entirely desk-based 
and did not involve any experimental measurements of pharmaceutical 
concentrations. The current study was therefore performed to generate actual 
measurements on the occurrence of pharmaceuticals in source and treated waters in 
England.  
 
The study considered a range of pharmaceutical compounds and their metabolites 
that have either a) high predicted exposure concentrations; b) toxicological concerns; 
or c) a low predicted exposure to therapeutic dose ratio. An illicit drug and its major 
metabolite were also investigated. The study compounds (in total 17) covered a 
range of chemical classes and varied in terms of their physico-chemical properties. 
The study was done at four sites where concentrations in source water at the 
drinking water treatment abstraction point were predicted to be some of the greatest 
in England. The study therefore is likely to provide a ‘worst case’ assessment of 
potential human exposure to pharmaceuticals in drinking water in England and Wales. 
 
Ten of the 17 study compounds were detected in untreated source waters at sub-µg/l 
concentrations. Six of these compounds (namely, benzoylecgonine (a metabolite of 
cocaine), caffeine, carbamazepine (an antiepileptic medicine), carbamazepine 
epoxide (a metabolite of carbamazepine), ibuprofen and naproxen (both non-
steroidal anti-inflammatory drugs) were also detected in treated drinking water. With 
the exception of carbamazepine epoxide, concentrations in treated drinking water 
were generally significantly lower than in source water. Even though England is a 
densely populated country and in some regions there is limited dilution of wastewater 
effluents, these observations, made at sites that were predicted to have some of the 
highest concentrations of pharmaceuticals in England and Wales, are in line with 
results from similar studies performed in other countries. 
 
Comparison of measured concentrations of the study compounds in drinking waters 
with information on therapeutic doses demonstrated that levels of these compounds 
in drinking water in England are many orders of magnitude lower than levels that are 
given to patients therapeutically. It would therefore appear that the low or non-
detectable levels of pharmaceuticals and illicit drugs present in drinking waters in 
England and Wales do not pose an appreciable risk to human health. 
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1. INTRODUCTION 
 
Pharmaceuticals play an important role in the treatment and prevention of disease in 
humans. Whilst the potential side effects on human and animal health arising from 
direct treatment have been widely documented, only recently have the implications of 
the occurrence, fate and effects of such medicines in the environment been 
considered (e.g. Daughton and Ternes, 1999; Boxall et al., 2004). 
 
A range of pharmaceuticals, including hormones, antibiotics, NSAIDS, 
antidepressants and antifungal agents have been detected in soils, surface waters 
and groundwaters (e.g. Hirsch et al., 1999; Kolpin et al., 2002). Whilst the reported 
concentrations are generally low (i.e. sub µg/l in surface waters), the substances 
have been observed throughout the year across a variety of hydrological, climatic 
and land-use settings. As a result, questions have been raised over the potential 
impacts, such as the promotion of the spread of antibiotic resistance, of 
pharmaceuticals in the environment on human health. 
 
Humans may be exposed to pharmaceuticals in the environment through the 
consumption of abstracted groundwater and surface waters containing 
pharmaceuticals or biologically active metabolites. While the health risks arising from 
this route of exposure in other geographical regions (e.g. USA) has been quantified, 
limited information is available on the potential exposure of the UK population. In the 
UK, we live on a densely populated island, with small rivers of limited dilution. 
Consequently, it might be expected that UK surface waters will have higher exposure 
to chemicals, including pharmaceuticals, than other developed countries. In common 
with many other developed countries, in a number of parts of the country discharges 
of treated sewage effluent occur in catchments that we use for drinking water 
abstraction.  
 
In a previous DWI funded study, simple modelling approaches were used alongside 
information on therapeutic doses of pharmaceuticals to identify pharmaceuticals that 
are likely to be of most concern in UK drinking water sources (Watts et al., 2007).  
However, the previous study was entirely desk-based and did not involve any actual 
measurements of pharmaceuticals in UK surface waters or use detailed information 
on toxicological profiles. This project therefore explored the actual levels of 
occurrence of pharmaceuticals in raw and treated waters in use in England.  
1.1. Objectives 
  
The objectives of the project were to: 
 
1. Identify three water treatment works in England or Wales considered to have a 
relatively high levels of human pharmaceuticals in the source and final waters;  
 
2. Select at least four human pharmaceuticals to monitor, where the selection must 
include: a compound with a high predicted concentration; a compound of high 
mammalian toxicity; a compound with a low margin of exposure (the ratio between 
the therapeutic dose and estimated intake); and an illegal drug; 
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3. Develop and validate analytical methodologies for the selected determinands with 
a detection limit of 10-100 ng/l or better; 
 
4. Devise and conduct a monitoring survey over a full calendar year for the selected 
compounds at the three sites selected under Objective 1 and at scenario B used in 
the previous DWI-funded study (Watts et al., 2007).  
 
5. Interpret the results obtained based on knowledge of the catchment conditions at 
the time of sampling and compare the results obtained for ‘scenario B’ with the 
estimates published in Annex 2 of the previous DWI report. 
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2. METHODS 
2.1. Pharmaceutical selection 
There are over 3,000 active pharmaceutical ingredients in use and it impossible to 
monitor all of these. A number of groups have therefore attempted to prioritise 
pharmaceuticals in terms of their potential to surface water and drinking waters and 
potential hazards to ecosystems and human health. Four prioritisation approaches 
are of relevant to pharmaceuticals in drinking water: 
 
1. Watts et al., (2007) – This approach used predicted environmental concentrations 
and the therapeutic dose of a compound to prioritise pharmaceuticals in use in the 
UK. Twenty four compounds with the highest exposure to dose ratios were 
identified. 
2. Besse and Garric (2008) – This approach used predicted environmental 
concentrations alongside data on metabolism, mode of action, ecotoxicity and 
toxicity to identify substances of potential concern in France. The final priority list 
included 40 parent compounds and 14 metabolites. 
3. A list developed for a nationwide drinking water monitoring study in the USA – In 
this study, data on predicted concentrations was combined with a review of 
toxicological data. 
4. Global Water Research Coalition (2008) – This study combined 25 prioritization 
reports to develop a list of priority pharmaceuticals for investigation in further 
studies. 
 
The prioritisation lists from each of these exercises were therefore obtained and 
combined (Appendix A). By selecting substances that appeared on three or more of 
the priority lists, a list of potential determinands (and associated metabolites) was 
developed (Table 1). These included a number of high exposure compounds as well 
as substances where toxicological concerns have been raised or compounds which 
have a low exposure to dose ratio (so they met the requirements of the project 
specification).  
Table 1 Potential determinands for the monitoring project 
 Parent compound Metabolites 
 
High exposure atenolol 
furosemide 
ibuprofen  
ketoprofen 
paracetamol 
sulfamethoxazole 
trimethoprim 
 
 
OH-ibuprofen, carboxy-ibuprofen 
 
 
acetylsulfamethoxazole 
Potential adverse  
toxicity 
carbamazepine 
diclofenac 
fluoxetine 
naproxen 
 
 
norfluoxetine 
Low ratio of exposure 
to dose 
atenolol 
atorvastatin 
furosemide 
ibuprofen 
simvastatin 
 
 
 
 
hydroxy-acid metabolite of simvastatin 
Illegal drug cocaine and its 
metabolites 
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From this list of potential determinands, a range of substances were selected for 
further study. The main factor considered in the final compound selection was that 
the selected compounds could be analysed using one extraction and detection 
method. Sulfamethoxazole and paracetomol and a number of metabolites were not 
taken forward for monitoring.  
 
In addition to the compounds identified in previous prioritisation studies, a cytotoxic 
drug, cyclophosphamide, was selected due to concerns over potential risks to human 
health (Rowney et al., 2009). The lipid lowering drug, orlistat, was also selected as it 
had recently become available as an over the counter medicine in the UK so use was 
expected to increase over the period of monitoring. Caffeine was included as a 
marker compound to give an indication of human inputs into the study catchments. 
 
The final list of determinands is shown in Table 2 along with information on physico-
chemical properties, and excretion by humans and fate in wastewater treatment. 
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Table 2. Pharmaceuticals, and associated metabolites, selected for study in the monitoring programme.  Structures, physico-chemical properties 
and available data on excretion by humans and removal in wastewater and drinking water treatment are shown. 
Compound Structure Class Use in England 
(Kg/yr)
!
 
Kow
#
 pKa Excreted 
unchanged (%) 
STP removal (%) 
Atenolol 
 
Β-blocker 27780 0.34 9.5 100 <10
+
 
benzoylecgonine 
 
cocaine 
metabolite 
 2.26 2.25, 11.2 45 of cocaine 
dose? 
- 
Caffeine 
 
stimulant - 0.091 0.6, 14 - 81-99.9
-
 
carbamazepine 
 
anti-epileptic 39069 1.90 - <1 17 (<10-53)
+
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Table 2. Continued 
Compound Structure Class Use in England 
(Kg) 
Kow# pKa Excreted 
unchanged (%) 
STP removal (%) 
carbamazepine 
epoxide 
 
carbamazepine 
metabolite 
 1.26 - - 0
@
 
cocaine 
 
elicit drug 22789 2.28 8.6 10-12 - 
cyclophosphamide 
 
chemotherapy 
agent 
11.6 0.23 9.91 25 - 
diclofenac 
 
non steroidal 
anti-
inflammatory 
151297 4.55 4.0 6-39 31 (<10-80)
+
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Table 2. Continued 
Compound Structure Class Use in England 
(Kg) 
Kow# pKa Excreted 
unchanged (%) 
STP removal (%) 
fluoxetine 
 
antidepressant 4640 3.93 10.1 ≤5 >90% 
furosemide 
 
diuretic 15210 3.10 9.83 65 0-75
&
 
ibuprofen 
 
non steroidal 
anti-
inflammatory  
262553 3.50 4.4 1 - 8 85.7 (52-99)
+
 
ketoprofen 
 
non steroidal 
anti-
inflammatory 
39959 2.91 5.94 <1 50-60* 
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Table 2. Continued 
Compound Structure Class Use in England 
(Kg) 
Kow# pKa Excreted 
unchanged (%) 
STP removal (%) 
naproxen 
 
non steroidal 
anti-
inflammatory 
53082 2.88 4.15 <1 72 (48-93)
+
 
norfluoxetine 
 
metabolite of 
fluoxetine 
- 4.36 - - >90 
orlistat 
 
anti-obesity 11434 8.95 - 100 - 
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Compound Structure Class Use in England 
(Kg) 
Kow
#
 pKa Excreted 
unchanged (%) 
STP removal 
(%) 
simvastatin 
 
hypolipidemic 43661 4.42 4.3 13 22-66^ 
trimethoprim 
 
antibiotic 8836 0.594 7.3 80 18.3 (<10-40)
+
 
! – based on NHS prescription data for 2009, # - Chemspider; + - Paxeus, 2004; % - Zorita et al., 2009; ^Lee et al., 2009 (data for other statins); - 
- Buerge et al., 2003; @ - Leclerq et al., 2009; & - Jacobsen et al., 2004; * - Kimura et al., 2007; ?- Zuccato et al. 2005 
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2.2. Site selection 
The aim of this task was to select three drinking water abstraction sites from rivers 
which would be expected to be at high risk of abstracting water containing 
pharmaceutical products. A fourth site, identified in the previous DWI study (Watts et 
al., 2007), was pre-selected. Since the main route of entry for pharmaceutical 
products is through waste water collection and treatment system, it was expected 
that these sites would be those below major centres of population.  
 
A previous study had estimated the concentrations of steroid oestrogens in rivers in 
England and Wales (Williams et al., 2009), including ethinyloestradiol (EE2), which is 
the active ingredient in the oral contraceptive pill. EE2 is known to pass through 
sewage treatment works (Johnson and Sumpter, 2001) and to be relatively persistent 
in river water (Jurgens et al., 2002). The concentrations of EE2 should therefore be 
indicative of concentrations of pharmaceuticals as a whole.  
 
For the initial site selection, we therefore assumed that river reaches with predicted 
higher concentrations of EE2 would also be expected to contain higher 
concentrations of other pharmaceutical products. Locations of drinking water 
abstraction points were therefore obtained from the Environment Agency and 
overlaid onto the map of EE2 concentrations in river waters in England and Wales. 
Abstraction points were then ranked in terms of their associated EE2 concentration. 
The top 30 sites on the ranked list were then taken forward for more detailed 
characterisation.  
 
Following the initial selection, additional information was sought about each of the 
sites through telephone conversations with water company staff responsible for the 
works. In addition to selecting sites which were highly ranked in terms of EE2 
concentrations, there were a number of other important selection criteria (both 
scientific and practical), which would all contribute to making these drinking raw 
water supplies vulnerable to pharmaceutical contamination which were determined in 
these interviews, namely: 
 
1. The abstraction identified was still in service. 
 
2. The abstracted water had to either enter the works directly from the river or 
only be stored for a short time in holding reservoirs prior to entering the works. 
This was to reduce the possibility of natural degradation of the 
pharmaceuticals during storage. 
 
3. If the water was stored in a holding reservoir, no water abstracted from other 
sources should also be stored in this reservoir.  If this was not the case then 
there was the possibility of dilution of high concentration water with low 
concentration water. 
 
4. The water supply should be reasonably high volume so it could be considered 
to be an important source. 
 
Following the telephone conversations five sites were visited to further assess their 
suitability. These included the site identified by Watts et al., (2007), which it should 
be noted would also have been selected by the methods used in this study validating 
its identification in the previous study as a high risk site. The main issue here was to 
double check that the information previously provided was as expected and to 
discuss the practicalities of access and sampling. In addition, information about the 
17 
 
treatment processes used at the works was also gathered. Of the five sites, four were 
suitable and were selected for monitoring (Table 3).  
 
Table 3. Characteristics of the selected study sites 
Site Rank# Abstraction and storage 
 
Treatment 
1 11 Water abstracted (100ML/day) from the 
river into a storage reservoir with a 
residence time of 12 hours 
flocculation, 
clarification, rapid 
gravity filters (sand 
and anthracite) 
GAC and 
chlorination 
2 23 Water abstracted directly from the river 
(~ 23 ML/day) into treatment 
flocculation, 
clarification, rapid 
gravity filters 
(including GAC), 
ozone and 
chlorination 
3* 15 Water abstracted from the river into a 
holding reservoir with a residence time 
of about 1 day 
clarification, ozone, 
rapid gravity filters, 
ozone again, GAC 
and chlorination 
 
4 2, 28 Water abstracted from two rivers into a 
storage reservoir which has a 
residence time of about 7 days.   
clarification, ozone, 
rapid gravity filters, 
ozone again, GAC 
and chlorination. 
 
# - based on modelled exposure of source water to EE2; * - Scenario B in previous 
project (Watts et al., 2007) 
2.3. Sampling 
Site monitoring was undertaken over a period of 12 months to reflect the potential 
temporal variations in pharmaceutical concentrations in both source and final waters 
at the four selected sites. 
2.3.1. Spot samples 
Samples were taken from the raw water that reaches the drinking water treatment 
plant and from the treated water that enters supply. For both types of water, monthly 
samples were taken manually in triplicate for all four sites.  Samples were placed in 
methanol-rinsed amber glass bottles (2.5 litre). Following collection, samples were 
placed in the dark, in cool-boxes containing frozen icepacks (at a temperature <8°C) 
and transported back to the laboratory for extraction and analysis.  
2.3.2. Passive samplers 
At two of the sites (Sites 1 and 3), passive samplers were also used. These devices 
accumulate analytes dissolved in the water into a receiving phase with a high affinity 
for the compounds of interest. The driving force for movement from the water to the 
receiving phase is diffusion, and so the rate of uptake by a sampler will depend on 
the difference between the chemical potentials of an analyte in the bulk water and in 
the receiving phase, and the structural properties (e.g. sampling area, presence and 
thickness of a diffusion limiting layer such as a the water boundary layer, and/or a 
polymeric membrane that separates the receiving phase from the bulk water 
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compartment).   The mass of analyte accumulated over the deployment period can 
be used to calculate the time weighted average concentration of an analyte in the 
water.  This can be achieved either by use of a theoretical relationship in which the 
physical and physicochemical parameters have been estimated, or by using 
laboratory calibration experiments. Passive samplers have been used for monitoring 
concentrations of pollutants in water since the 1990’s.  Most of the early work in this 
areas concentrated on the measurement of non-polar compounds (LogKow >3). 
 
The passive monitoring in this survey utilised the Chemcatcher® passive sampler. 
Chemcatcher® samplers, comprising a receiving phase (SDB-XC EmporeTM disk), 
and diffusion limiting membrane (polyethersulphone) held in a PTFE housing were 
used. In order to tailor the exposure of the samplers to the local conditions in the 
water treatment plants, an over-flow deployment device consisting of a stainless steel 
tank and water reservoir that is connected to a copper piping distribution system was 
designed and used. A constant level of water was maintained in the plastic reservoir 
by a continuous flow of raw and final drinking waters from taps on plant distribution 
pipes. Water was forced through the copper pipes by the head of pressure 
maintained in the plastic reservoir, and in this way a turbulent flow was maintained 
over the sampling surfaces of the Chemcatcher® samplers.  The passive samplers 
were deployed between February 2010 and August 2010 on a monthly basis (at Site 
3 it was not possible to monitor for the whole period due to site closures). On sampler 
retrieval dates, chemcatchers® were removed from the cage and water was added 
before closing the transport lid. 
 
In order to derive time-weighted average concentrations from the passive sampler 
measurements of pharmaceutical mass, a calibration study was done at the 
University of Portsmouth for atenolol, benzoylecgonine, caffeine, carbamazepine, 
cocaine, diclofenac, furosemide, ibuprofen, ketoprofen, naproxen and trimethoprim. 
Two compounds (norfluoxetine and fluoxetine) were omitted from the calibration 
study because of the high costs of analytical standards, and the large quantities 
needed to maintain the high flow rate of spiked calibration water. 
 
Samplers were attached to the aluminium mesh lid of a calibration tank so that the 
sampling face was constantly immersed. A flow of water, spiked with the 
pharmaceuticals of interest, was then maintained through the system. 
Pharmaceuticals were introduced in a methanolic spiking solution (2 mg l-1 of each 
compound) using an HPLC pump (0.2 mL min-1) into a copper tube carrying a flow 
(~2 L h-1) of tap water regulated by a needle valve.  The overall flow rate was 
selected on the basis of field measurements in the two water treatment plants.  The 
stock solution of pharmaceuticals was stirred constantly using a magnetic stirrer.  
Spot samples of water were taken frequently, extracted using Empore disks SDB-XC, 
and analysed by LC-MS-MS. Temperature, pH and water flow were checked 
regularly, and 5 Chemcatcher blanks were used to check for laboratory 
contamination. The mass of each analyte accumulated by the devices at a range of 
deployment times was then determined.   
 
In the integrative phase there is a straight line relationship between the mass 
accumulated and elapsed time from deployment (equation 1). The slope of this 
calibration curve has units of mass per time. 
 
Cw = mt/Rst                            Eqn 1 
                                                                                                                                                                                                                               
Where Cw is the concentration in the water, mt is the mass accumulated in the 
sampler after a deployment time of t, and Rs is the sampling rate under the 
calibration conditions. 
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Rs is calculated by dividing the slope of the calibration curve by the concentration of 
analyte in the water.  This can then be used to calculate the time weighted average 
(TWA) concentration of an analyte under field conditions that match those used in the 
laboratory by measuring the mass (mt) accumulated over a deployment time t, and 
substituting the values into equation 1. 
2.4. Pharmaceutical analysis 
2.4.1. Spot sample extraction, clean-up and concentration 
Samples of treated and raw waters (typically 1 litre) were pH adjusted (pH 7.5-8.2) 
and appropriate internal standards added prior to loading onto a pre-conditioned 
Waters HLB solid Phase Extraction SPE) (cartridge (200mg/6ml) . The loading rate 
did not exceed 10 ml/min and the eluate was discarded.  The cartridge was washed 
with water (5 ml) before air drying (under vacuum) for at least 30 minutes.  The 
analytes were then eluted with methanol (8 ml) and then concentrated, under a 
stream of nitrogen, to a low volume (approximately 50 µl). The extract was 
reconstituted to a volume of 1 ml using a 90:10 solution of water/methanol prior to 
analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). 
 
For some samples it was necessary to use up to three SPE cartridges and to 
combine the eluates.  In cases where it was not possible to load 1000 ml of sample, 
the remaining volume was measured and the measured concentrations of analytes 
corrected accordingly. 
 
All sample batches included a blank sample (tap water) and samples over-spiked 
with analytes of interest at different concentrations to assess analytical recovery for 
those compounds for which labelled internal standards were not available.  All 
measurements were based on matrix-matched calibration standards. 
2.4.2. Passive sampler extraction 
After collection, sampler devices were processed as follows: chemcatchers® were 
rinsed with distilled water and disassembled in a clean area. PES membranes were 
removed from the top of the disk with clean stainless steel tweezers and the disks 
were placed on the vacuum manifold and dried for approximately 30 minutes or until 
dried. Each disk and SDB-XC Empore™ disks were eluted with 18 ml of methanol 
(HPLC grade). Deuterated compounds were spiked into extracts to correct for 
recoveries and extracts were reduced to dryness using a gentle nitrogen flow. 
Samples were then redissolved in 1 ml of 90:10 solution of water/methanol and sent 
for LC-MS analysis. 
2.4.3. LC-MS/MS analysis 
LC-MS/MS analyses were performed using a Waters Acquity Ultra-Performance 
Liquid Chromatography (UPLC) system (Waters, Milford MA, US).  Chromatography 
was performed using a UPLC HSS T3 C18 column (100 x 2.1 mm I.D., 1.8 µm 
particle size, Waters, Milford MA, US), maintained at 40ºC, with a mobile phase flow 
rate of 0.5 ml/min.  The mobile phase compositions were 5 mM ammonium acetate in 
water (A) and methanol (B).  Gradient elution was employed, starting at 2% B and 
rising linearly to 50% B over 4 minutes then it was held for 0.3 min at 50% B. Then 
from 4.3 min to 8 min gradient elution continued from 50%B to 98%B.  The 
composition was held at 98 % B for 3 minutes before returning to the initial conditions, 
followed by re-equilibration for 2 minutes, giving a total cycle time of 13 minutes.  The 
injection volume of extracts was 20 µl.  These UPLC conditions provided the best 
compromise between speed and chromatographic performance.  Separation 
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between compounds was sufficient for polarity switching to allow all compounds to be 
acquired in a single run.  
 
The Waters Premier XE LC-MS/MS parameters giving the best overall results were; 
Capillary Voltage (3000V - positive mode, 2800V – negative mode) Cone Voltage 
(10-40V), Desolvation Temp (450 °C), Source Temp (120°C), Cone Gas Flow (100 
L/hr) and Desolvation gas flow (900 L/hr). Cone voltage and Collision Energy were 
optimised for each analyte. Further details for individual compounds including MS/MS 
transitions are provided in Table 4.  
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Table 4. Summary of UPLC-MS/MS parameters and limits of detection for the analytical method 
 tR (min) MRM transitions CV (V) CE (eV) Internal std LoD* (ng/l) 
 
atenolol 2.15 267.3-145 
267.3-190.1 
32 26 
18 
Atenolol d7 2 
benzoylecgonine 3.46 290.3-168.1 
290.3-105 
32 20 
28 
Benzoylecgonine 
d8 
1 
caffeine 3.17 195.2-138 
195.2-110 
32 20 
24 
Caffeine 13C3 2 
carbamazepine 5.48 237.3-194.1 
237.3-179.1 
30 20 
34 
Carbamazepine 
d10 
1 
carbamazepine 
epoxide 
4.7 253.2-180 
253.2-236.1 
18 28 
12 
- 1 
cocaine 5.1 304.3-182.1 
304.3-105  
32 20 
32 
- 5 
cyclophosphamide 4.65 261-139.9 
261-105.9 
28 22 
18 
- 1 
diclofenac 5.8 294-249.9 
294-213.9 
22 12 
18 
- 10 
fluoxetine 6.2 310.3-44.2 
310.3-148.1 
20 12 
8 
Fluoxetine d5 5 
furosemide 3.88 331.1-81.1 10 10 - 5 
Ibuprofen 6 205-160.9 22 6 Ibuprofen d3 2 
ketoprofen 4.9 255.3-209.1 
255.3-105.1 
28 14 
24 
- 1 
naproxen 4.85 231.2-185.1 
231.2-170 
20 
 
14 
26 
- 1 
norfluoxetine 6.15 296.3-134.1 
296.3-30.5 
12 
 
6 
8 
- 10 
orlistat 8.7 518.5-182.1 
496.5-319.4 
496.5-114.1 
47 
26 
26 
22 
12 
28 
- 10 
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 tR (min) MRM transitions CV (V) CE (eV) Internal std LoD* (ng/l) 
 
simvastatin 7.85 441.4-325.3 
419.4-285.3 
419.4-199.2 
52 
20 
20 
24 
10 
18 
- 50 
trimethoprim 3.9 291.3-123.1 
291.3-230.2 
36 30 
22 
- 5 
* - Slight variations in LOD did occur for some compounds during the study 
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3. RESULTS 
 
Results of the 12-month monitoring study are presented below. Due to temporary site 
closures, it was not possible to take samples of treated water from Site 3 in January 
to May and June 2010, source water from Site 3 in March and April and June and of 
source and treated water from Site 2 in February 2010 (Table 5). Passive sampler 
data were only generated for the period February to Aug 2010 from Site 1 and for 
May, July and Aug 2010 for Site 3.  
 
Table 5. Dates of sampling of raw and treated water at the four study sites. A – 
indicates that a sample was not taken due to site closure. SW = untreated water; TW = 
treated water. 
sampling Site 1 Site 2 Site 3 Site 4 
  SW TW SW TW SW TW SW TW 
1 20/09/09 22/09/09 
2 20/10/09 21/10/09 
3 17/11/09 19/11/09 
4 15/12/09 16/12/09 
5 12/01/10 15/01/10 - 19/01/10 
6 9/02/10 - 9/02/10  - 9/02/10 
7 9/03/10 - 9/03/10 
8 6/04/10 - 7/04/10 
9 4/05/10 5/05/10 
10 2/06/2010 1/06/10 - 2/06/10 
11 25/06/10 28/06/10 5/07/10 
12 27/07/2010 27/07/10 
13 24/08/2010 24/08/10 
 
3.1. Spot samples 
 
Mean monthly concentrations at each site are presented in Appendix B and a 
summary of the concentrations in spot samples is presented in Table 6 (in instances 
where concentrations in a replicate was lower than the limit of detection, a value of 
zero was assumed). Cocaine, cyclophosphamide, fluoxetine, norfluoxetine, 
ketoprofen and orlistat were not detected in any of the spot samples obtained from 
any of the sites. Atenolol, diclofenac, furosemide and trimethoprim were detected in 
source water samples from all four sites (Table 6; Figures 1-4) but were not detected 
in treated drinking water samples. 
 
Benzoylecgonine, caffeine, carbamazepine, carbamazepine epoxide, ibuprofen and 
naproxen were detected in both untreated source water and treated water (Figures 
5a and b -10a and b). With the exception of carbamazepine epoxide at Sites 2 and 4, 
and carbamazepine at site 2 on one sampling occasion, concentrations in treated 
water were significantly lower than in the source waters.  
 
Estimated removal efficiencies for the study compounds ranged from 69-100% for 
benzoylecgonine, 51-100% for caffeine, -6.91-100% for carbamazepine,  -131-100% 
for carbamazepine epoxide, 89-100% for ibuprofen and 89-100% naproxen (Figures 
5c -10c).  
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Table 6. Median concentrations (ng/l) (based on the mean monthly values) for the study 
compounds in source and treated waters at the study sites. Values are obtained from 
means for each sampling period. Ranges are provided in parentheses. 
 site 1 site 2 site 3 site 4 
 source treated source treated source treated source treated 
atenolol 38.8 (18.1 
– 66.3) 
<2 53.0 (31.2 
– 91.2) 
<2 18.4 (8.2 
– 67.6) 
<2 25.3 (19.6 
– 114) 
<2 
benzoylecgonine 1.2 (<1 – 
2.06) 
<1 3.12 (<1 
– 5.77) 
<1 2.85 (1.25 
– 4.80) 
<1 9.80 (1.99 
– 16.3) 
1.98 (<1 – 
3.51) 
caffeine 176  (86.7 
– 441) 
15.7 (7.56 
– 79.3) 
93.8 (63.7 
– 224) 
8.75 (3.05 
– 46.3) 
102 (54.7 
– 199) 
4.05 (<2 – 
8.83) 
227 (82.2 
– 329) 
13.5 (<2 – 
29.2) 
carbamazepine 86.3 (49.4 
– 199) 
11.8 (8.37 
– 17.3) 
139 (45.0 
– 277) 
2.88 (1.22 
– 148) 
255 (34.3 
– 555) 
<1 (<1 – 
1.25) 
185 (16.4 
– 480) 
1.03 (<1 – 
3.96) 
carbamazepine 
epoxide 
6.53 (2.83 
– 11.3) 
3.89 (2.27 
– 6.10) 
7.50 (2.47 
– 19.7) 
4.92 (2.88 
– 16.6) 
13.2 (<1 
– 24.7) 
4.45 (<1 – 
6.01) 
7.62 (1.12 
– 16.7) 
6.24 (1.93 
– 10.7) 
cocaine <5 <5 <5 <5 <5 <5 <5 <5 
cyclophosphamide <1 <1 <1 <1 <1 <1 <1 <1 
diclofenac <10 (<10 
– 24.3) 
<10 12.3 (<10 
– 39.0) 
<10 12.6 (<10 
– 76.3) 
<10 11.9 (<10 
– 47.1) 
<10 
fluoxetine <5 <5 <5 <5 <5 <5 <5 <5 
furosemide 6.44 (<5 
– 28.9) 
<5 17.0 (<5 
– 43.1) 
<5 <5 (<5 – 
36.0) 
<5 13.3 (<5 
– 63.5) 
<5 
ibuprofen 19.4 (6.33 
– 30.8) 
<2 (<2 - 
3.07) 
10.2 (<2 
– 38.4) 
<2 6.77 (<2 
– 21.5) 
<2 17.1 (<2 
– 38.2) 
<2 
ketoprofen <1 <1 <1 <1 <1 <1 <1 <1 
naproxen 17.3 (10.2 
– 26.4) 
<1 17.7 (6.93 
– 42.2) 
<1 12.4 (4.85 
– 28.9) 
<1 21.7 (11.1 
– 44.4) 
<1 (<1-
2.72) 
norfluoxetine <10 <10 <10 <10 <10 <10 <10 <10 
orlistat <10 <10 <10 <10 <10 <10 <10 <10 
simvastatin <50 <50 <50 <50 <50 <50 <50 <50 
trimethoprim 11.0 (<5 
– 13.8) 
<5 10.4 (<5 
– 13.8) 
<5 <5 (<5 – 
8.27) 
<5 6.1 (<5 – 
26.4) 
<5 
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Figure 1. Mean concentrations (±S.D) of atenolol in untreated source waters at the four 
study sites.  
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Figure 2. Mean concentrations (±S.D) of diclofenac in untreated source waters at the 
four study sites.  
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Figure 3. Mean concentrations (±S.D) of furosemide in untreated source waters at the 
four study sites. 
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Figure 4 Mean concentrations (±S.D) of trimethoprim in untreated source waters at the 
four study sites. 
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Figure 5. Mean concentrations (±S.D) of benzoylecgonine in A) untreated source waters 
and B) treated drinking water at the four study sites. Graph C indicates the treatment 
efficiency for removal of the compound at the four sites. 
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Figure 6. Mean concentrations (±S.D) of caffeine in A) untreated source waters and B) 
treated drinking water at the four study sites. Graph C indicates the treatment 
efficiency for removal of the compound at the four sites. 
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Figure 7. Mean concentrations (±S.D) of carbamazepine in A) untreated source waters 
and B) treated drinking water at the four study sites. Graph C indicates the treatment 
efficiency for removal of the compound at the four sites. 
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Figure 8. Mean concentrations (±S.D) of carbamazepine epoxide in A) untreated source 
waters and B) treated drinking water at the four study sites. Graph C indicates the 
treatment efficiency for removal of the compound at the four sites. 
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Figure 9. Mean concentrations (±S.D) of ibuprofen in A) untreated source waters and B) 
treated drinking water at the four study sites. Graph C indicates the treatment 
efficiency for removal of the compound at the four sites. 
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Figure 10. Mean concentrations (±S.D) of naproxen in A) untreated source waters and B) 
treated drinking water at the four study sites. Graph C indicates the treatment 
efficiency for removal of the compound at the four sites. 
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3.2. Passive samplers 
The masses of individual pharmaceuticals recovered in the receiving phase of the 
Chemcatchers are given in Appendix C and estimated water concentrations are 
given in Appendix D.  
 
Field blank passive samplers were used to check for laboratory contamination during 
preparation.  One blank per field visit was used at Site 1, and two at Site 3.  Atenolol, 
benzoylecgonine, diclofenac, furosemide, ibuprofen and ketoprofen were not 
detected in any of the blanks. Carbamazepine, cocaine and diclofenac were each 
detected in one out of the ten blank samples at amounts close to the analytical limit 
of detection. Trimethoprim was detected in three of the ten blanks at amounts close 
to the LOD. Caffeine was detected in seven out of ten blanks, in six of these the 
levels were close to the LOD. Concentrations of fluoxetine and for norfluoxetine in 
the blanks were high compared to samples of raw and treated waters. Based on 
these findings it was concluded that the results for fluoxetine and norfluoxetine were 
unreliable so these data are not discussed further. For other substances that had 
been regularly been seen in the blank samples, the results were blank corrected by 
deducting the masses seen on the blank samplers from the masses seen on the raw 
and treated water samplers.  
 
The results for the passive samplers deployed in source water and treated water are 
summarised in Table 7. Benzoylecgonine, cocaine and ketoprofen were not detected 
in any sample. Caffeine, ibuprofen, naproxen, carbamazepine, atenolol, and 
diclofenac were detected in one or more of the passive samplers and it was possible 
to estimate corresponding time-weighted average (TWA) concentrations in water for 
these substances (Table 7). While trimethoprim and furosemide were detected in 
some of the passive samplers, due to problems with the calibration experiments (i.e. 
neither compound was detectable in the calibration tank water or the calibration 
samplers), it was not possible to estimate TWA concentrations for these substances. 
Data for these two compounds are therefore only presented as either ‘detected’ or 
‘non-detected’.  
 
Results obtained from the passive sampling at the two study sites are compared to 
the results of the spot sampling in Figures 11 and 12. There was fair agreement 
between the concentration estimates obtained from passive sampling with measured 
concentrations in spot samples for atenolol and caffeine (Figures 11 and 12). For 
ibuprofen and naproxen there was a poorer agreement in numerical terms, but 
reasonable agreement in terms of presence or absence in individual sampling 
periods. For carbamazepine the estimated concentrations at Site 1 from passive 
sampling were considerably higher than measurements from spot sampling (Figure 
11). In contrast, at Site 3, estimated concentrations from the passive samplers were 
lower than concentrations detected in the spot samples (Figure 12). Diclofenac was 
only rarely detected in either passive samplers or spot samples and there was limited 
agreement between the two approaches in terms of presence or absence of the 
compound.    
 
The mismatch between the passive sampler results and spot sample data may be 
due to the large uncertainties in the indicative sampling rates. Low sampling rates 
(less than 10 ml d-1) were seen for the passive samplers in the calibration 
experiments. The regression line calibration fits were also poor for many of the study 
compounds (Appendix E; e.g. for carbamazepine, an r2 value of only 0.24 was 
obtained). These uncertainties are probably a function of the low temperature, and 
poor turbulence in the calibration experiments (as these were set up to mimic the 
field sampling conditions, similar low rates would be expected in the field). Much 
34 
 
higher sampling rates (in the range of 10’s – 100’s ml d-1) are usually seen under 
conditions of higher turbulence that are more typical of situations where passive 
samplers have been successfully used in field monitoring investigations in the past. 
The uptake of pharmaceuticals may also have been affected in both laboratory and 
field by the accumulation of lime scale from the tap water, and aluminium hydroxide 
produced by the effects of the water on the aluminium deployment mesh, and in a 
few cases bacterial growth on the diffusion limiting membranes. The differences in 
relationships between passive and spot sample data at the two study sites, 
particularly for carbamazepine, also indicates that the samplers may have performed 
differently at the two study sites. 
  
Table 7. Time weighted average concentration ranges (ng/l) from the seven passive 
sampling periods at Sites 1 and the three passive sampling periods at Site 3.  
 site 1 site 3 
 source treated source treated 
atenolol 23 - 118 ND ND ND  
benzoylecgonine ND ND ND ND 
caffeine 53 - 234 ND - 55 27- 69 ND – 17 
carbamazepine 80 - 2013 37 - 373 13 - 183 ND – 154 
cocaine ND ND ND ND 
diclofenac ND - 96 ND ND ND 
furosemide Detected ND ND ND 
ibuprofen 14 - 90 ND ND ND 
ketoprofen ND ND ND ND 
naproxen 16 - 97 ND ND  ND 
trimethoprim Detected ND Detected ND 
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Figure 11. Comparison of time weighted average concentrations, obtained using 
passive samplers, in source waters and treated waters at Site 1 with concentrations 
from spot samples 
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Figure 12. Comparison of time weighted average concentrations, obtained using 
passive samplers, in source water and treated waters at Site 3 with concentrations 
from spot samples 
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4. DISCUSSION 
In the previous DWI funded study, simple modelling approaches were used alongside 
information on therapeutic doses of pharmaceuticals to identify substances that are 
likely to be of most concern in UK drinking waters. This previous study was entirely 
desk-based and did not make any measurements of pharmaceutical concentrations 
in water in England and Wales. A major recommendation from the previous study 
was that a targeted monitoring programme be performed to assess actual levels of 
exposure of pharmaceuticals in source waters and treated waters in England and 
Wales. The current project therefore addressed this knowledge gap by exploring the 
occurrence of pharmaceuticals in raw and treated waters in England.  
 
The study considered a range of pharmaceutical compounds that have either a) high 
predicted exposure concentrations; b) toxicological concerns; or c) a low predicted 
exposure to therapeutic dose ratio. An illicit drug and its major metabolite were also 
investigated. The study compounds covered a range of chemical classes and varied 
in terms of their physico-chemical properties. The study was done at four sites where 
concentrations in source water at the drinking water treatment abstraction point were 
predicted to be some of the greatest in England. 
4.1. Comparison of measurements for source waters with previous 
UK monitoring studies and predictions from previous DWI study 
 
Ten of the 17 study compounds were detected in untreated source waters at sub-µg/l 
concentrations (based on spot sample data). A number of the study compounds have 
been studied in previous monitoring studies in the UK (Ashton et al., 2004; Thomas 
and Hilton, 2004; Roberts and Thomas, 2006; Boucard et al., 2006; Kasprzyk-
Hordern et al., 2009). Concentration ranges seen in the current study were within the 
ranges reported in these previous studies (Table 8). 
 
In the previous DWI-funded study, pharmaceuticals were prioritised based on their 
predicted exposure concentrations in drinking waters. Site 3 was used as a basis for 
this previous modelling work. A previous modelling study has also predicted the 
potential exposure concentrations of cytotoxic drugs in a UK catchment (Rowney et 
al., 2009). Comparison of the exposure predictions from these previous studies with 
measurements made in the current study at Site 3 showed that, with the exception of 
carbamazepine, measured concentrations in source waters were at least an order of 
magnitude lower than concentrations predicted for drinking water (Table 8).This is 
not surprising because of the worst case assumptions made in the Watts et al study. 
The rank order of exposure concentrations for the compounds was also different 
between the previous DWI-funded study and the current study.  
 
The differences between the predicted and measured concentrations are probably 
explained by the fact that, due to lack of data on the fate and behaviour of 
pharmaceuticals in the environment, a simplistic modelling approach was used in the 
previous DWI project for determining exposure. This simple model did not consider 
either metabolism in the treated patient, or the potential for dissipation of a 
pharmaceutical between the wastewater effluent discharge and the drinking water 
abstraction point. Removal of pharmaceuticals during wastewater treatment was only 
considered if experimental data were available. The pharmaceutical usage data 
employed in the previous study was taken from 2004 so it is also possible that 
pharmaceutical usage has changed – this might explain the observations for 
carbamazepine where measured concentrations are higher than predicted 
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concentrations in source waters. The previous study did make it quite clear that the 
predicted values will be worst case estimates. 
 
Table 8 Comparison of measured concentrations from this study with previously 
measured values or previously predicted concentrations. Data median values (ranges 
in parentheses.  
 Previously 
predicted 
concentration 
for site 3 
(ng/l)
>
 
Median 
measured 
source water 
concentration 
for site 3 
Median 
measured 
treated water 
concentrations 
for site 3 
Results from 
previous 
monitoring in 
the UK (ng/l) 
atenolol 8360 18.4 (8.2 – 67.6) <2 <1 – 560
+
 
benzoylecgonine - 2.85 (1.25 – 4.80) <1 - 
caffeine - 102 (54.7 – 199) 4.05 (<2 – 8.83) - 
carbamazepine 23 255 (34.3 – 555) <1 (<1 – 1.25) 1 – 647
+
 
carbamazepine 
epoxide 
- 13.2 (<1 – 24.7) 4.45 (<1 – 6.01) - 
cocaine 2530 <5 <5 - 
cyclophosphamide 70.2 <1 <1 - 
diclofenac 5000 12.6 (<10 – 76.3) <10 <LOQ (568)
$
 
<LOQ
&
 
<0.5 – 261
+
 
fluoxetine 88.2 <5 <5 2 – 43.78* 
ibuprofen 18920 <5 (<5 – 36.0) <5 826 (5044)
$
 
297 (2370)
#
 
48 (930)
&
 
<0.3 – 74
+
 
furosemide 5270 6.77 (<2 – 21.5) <2 <6 – 636
+
 
ketoprofen 230 <1 <1 <0.5 – 12
+
 
naproxen 6330 12.4 (4.85 – 28.9) <1 <0.3 – 146
+
 
norfluoxetine - <10 <10 4.5 – 83* 
orlistat 1540 <10 <10 - 
simvastatin 3240 <50 <50 <50
+
 
trimethoprim 1270 <5 (<5 – 8.27) <5 <LOQ (42)
$
 
9 (19)
#
 
7 (569)
&
 
<0.5 – 120
+
 
> 
- predicted values taken from Watts et al., 2007 except cyclophosphamide which was obtained from 
Rowney et al., 2009; 
$
 - Ashton et al., 2004; 
&
 - Thomas and Hilton, 2004; *- Boucard et al., 2006; 
#
 - 
Thomas and Hilton, 2004; 
+
 - Kasprzyk-Hordern et al., 2009. 
?
 – concentration range from passive 
samplers 
 
In order to establish whether metabolism, removal in treatment or discrepancies in 
usage data do account for the differences between measurements and predictions 
from the previous project, exposure estimates were revised using more recent usage 
data, metabolism information and removal in treatment and Equation 2.  
 
 DV x 
 )F- (1 x FA x 
  PEC
remexc
                              Equation 2 
 
Where: PEC = predicted environmental concentration (mg/l); A = dose of 
pharmaceuticals (mg/capita/d; obtained from prescription data for England for 2009); 
Fexc = Fraction excreted by patient; Frem = Fraction removed in wastewater 
treatment works; V = Volume of wastewater per capita per day (default 147 l); D = 
Dilution factor for wastewater in receiving water (default 10). A population value of 
51.4 Million was used in the calculations. 
 
Revised exposure estimates were significantly lower than obtained in the previous 
DWI study. Estimates for furosemide and naproxen were within an order of 
magnitude of the measured values in source waters (Table 9). However there were 
still large discrepancies between predictions and measurement for diclofenac, 
ibuprofen and carbamazepine (Table 9). The application of a more complex model 
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that also considers fate in surface waters might improve the estimates for some of 
these substances. 
4.2. Temporal and spatial variations in concentrations in source 
waters 
Concentrations of the study compounds varied across the four study sites. There was 
however no clear pattern and there was no one site that had consistently higher 
concentrations than the other sites for all pharmaceuticals. Possible explanations for 
this could be differences in pharmaceutical prescribing patterns in the regions studied, 
differences in the design and performance of wastewater treatment works in the 
study catchments or differences in the dissipation behaviour of the study compounds 
between the emission to surface water and the drinking water abstraction points at 
the individual study sites. 
 
Concentrations of the study compounds at each of the study sites also varied across 
the year. Differences in concentration between sampling occasions at a study site 
might be explained by variations in: a) prescribing patterns; b) river flows; and c) 
differences in dissipation rates in wastewater treatment processes and surface water 
bodies in a catchment over the year. These factors are discussed in more detail 
below.  
 
Data are available from the National Health Service Information Centre on the 
number of prescriptions (by drug class) made by Primary Care Trusts in the UK on a 
quarterly basis. Data were therefore obtained on prescriptions of the different drug 
classes investigated in the study (Figure 13).  
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Figure 13. Total prescriptions for the study pharmaceutical compound classes for 
England. Derived from Primary Care Trust prescription data from the NHS Information 
Centre. 
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Table 9 Comparison of measured concentrations of the study compounds with concentrations predicted using a simple model 
Compound Use in England 
(kg/yr) 
Excreted 
unchanged (%) 
STP removal (%) Median 
measured 
concentration 
(ng/l) 
PEC (ng/l) MEC:PEC 
atenolol 27780 100 10 40 (8.2 – 114) 907 0.04 
carbamazepine 39069 1 17 132 (16.4 – 555) 11.8 11.2 
cyclophosphamide 11.6 25 0 <5 0.1 NA 
diclofenac 151297 22.5 31 10.6 (<10 – 76.3) 852 0.01 
fluoxetine 4640 5 90 <5 0.8 NA 
furosemide 15210 65 37.5 9.6 (<5 - 63.5) 224 0.04 
ibuprofen 262553 4.5 85.7 11.7 (<2 - 38.4) 61.3 0.19 
ketoprofen 39959 1 55 <1 6.5 NA 
naproxen 53082 1 72 17.0 (4.9 - 44.4) 5.4 3.1 
orlistat 11434 100 0 <10 415 NA 
simvastatin 43661 13 44 <50 115 NA 
trimethoprim 8836 80 18.3 8.0 (<5 - 26.4) 209 0.04 
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With the exception of the antibacterial class, where use from October to December 
was around 17-20% greater than use from April to September, there was little 
variation in the usage of the different classes of pharmaceutical studied (Figure 17). 
The data therefore suggest that, with the exception of trimethoprim, variations in 
concentration over time are not caused by variations in use of a particular compound. 
 
Data on river flows in England and Wales are collected by the Environment Agency. 
Flow data for the nearest gauging station to each site for the full study period are 
shown graphically in Appendix F. In order to explore whether differences in 
concentrations over time could partly be explained by differences in river flows, 
relationships between flow data and concentrations of carbamazepine were explored. 
Carbamazepine is recalcitrant in the environment so is a good compound for this 
type of analysis. For all sites, there was a trend towards lower carbamazepine 
concentrations at higher flow rates (Figure 14) although this did not explain all the 
variability in measured concentrations. The results therefore indicate that river flow is 
an important factor in determining pharmaceutical concentrations but, even for a 
compound like carbamazepine, river flow alone does not explain all the variation in 
observed concentrations. 
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Figure 14. Relationship between measured concentrations of carbamazepine in source 
water and river flow rate at the four study sites over the study period. 
4.3. Concentrations in drinking waters 
Six of the 17 study compounds were detected in treated drinking water at the study 
sites, namely benzoylecgonine, caffeine, carbamazepine, carbamazepine epoxide, 
ibuprofen and naproxen. With the exception of carbamazepine epoxide, 
concentrations in the treated drinking water were significantly lower than in the 
source waters. The measured concentrations of the study compounds in drinking 
water samples were in good agreement with concentrations measured previously in 
similar studies that have monitored the study pharmaceuticals in drinking water in the 
USA, Canada, Spain and Sweden (Table 10).  
 
By comparing monthly concentrations in both source water and treated drinking 
water, it is possible to develop a rough estimate of the removal efficiencies for the 
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study compounds in the treatment works that were investigated. Removal efficiencies 
for atenolol, diclofenac, furosemide and trimethoprim were 100% at all study sites on 
all sampling occasions. Estimated removal efficiencies for the other study 
compounds ranged from 69-100% for benzoylecgonine, 51-100% for caffeine, 77 -
100% for carbamazepine (on one occasion removal was -6.91% at one site),  -131-
100% for carbamazepine epoxide, 89-100% for ibuprofen and 89-100% naproxen 
(Table 11). With the exception of carbamazepine epoxide, these removal efficiencies 
are in good agreement with removal efficiencies seen in similar studies elsewhere 
(Table 11). 
 
Table 10 Comparison of measured concentrations in drinking water from this study 
with measured concentrations from previous studies. Results from previous studies 
are either presented at mean or media concentrations with maximum concentrations in 
parentheses or as maximum concentrations  
 Results from previous 
monitoring (ng/l) 
Concentration in drinking 
water 
(ng/l) 
atenolol 1.2 (18)
+
 
12 (23)
$
 
<0.1 – 1.3
@
 
<2 
caffeine 119* 
ND
&
 
11.2 (<2 – 79.3) 
ND – 69
?
 
carbamazepine 6.0 (18)
+
 
ND
$
 
0.21 (601)
#
 
258* 
2.3 (<1 – 148) 
ND – 373
?
 
carbamazepine epoxide 2 (1)
$
 14.5 (<1 – 16.6) 
diclofenac ND
+
 
<0.1 – 0.7
@
 
<10 
fluoxetine 0.7 (0.82)
+
 
ND
^
 
ND* 
<5 
ibuprofen ND
^
 
0.33 (25)
#
 
ND* 
<0.1 – 1.3
@
 
<2 (<2 – 3.07) 
 
furosemide ND
$
 
ND* 
<0.7 – 1.5
@
 
<5 
naproxen ND
+
 
ND
^
 
<1 – 1.3
@
 
<1 (<1 – 2.72) 
norfluoxetine ND
+
 <10 
trimethoprim ND
+
 
ND* 
<0.3 – 0.5
@
 
<5 
+
 - Benotti et al., 2009; 
^
 - Boyd et al., 2003; 
$
 - Huerta-Fontela et al., 2011; 
#
 - Kleywegt et al., 
2011; * - Stackelberg et al., 2004; 
&
 -Stackelberg et al., 2007; 
@
 - Wahlberg et al., 2011; ? – 
passive sampling data 
 
Concentrations of carbamazepine epoxide were higher in a number of drinking water 
samples obtained Sites 2 and 4 than the corresponding source water concentrations. 
One possible explanation for the some of the observed increases in concentration for 
this compound is that the treatment processes at these two plants convert the parent 
carbamazepine that occurs in source waters to the epoxide. Work by Kotcharaksa 
(2008) into the degradation mechanisms of carbamazepine during chlorination 
supports this hypothesis. In this study, carbamazepine epoxide was observed to be 
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one of the reaction intermediates formed during the chlorination of carbamazepine 
(Figure 15). This highlights the importance of considering the potential risks of 
transformation products of pharmaceuticals in drinking waters. 
Table 11 Comparison of removal efficiencies for the study drinking water treatment 
plants with previously reported removal efficiencies for conventional treatment plants.  
  
Removal in drinking water treatment  (%) 
 
 
Reference 
 Current study Previous studies  
 
atenolol 100 97 Huerta-Fontela et 
al., 2011 
benzoylecgonine 69 - 100 82 Huerta-Fontela et 
al., 2008 
caffeine 51 - 100 88 Stackelberg et al., 
2007 
carbamazepine 77* - 100 85 - >99 Stackelberg et al., 
2007; Huerta-
Fontela et al., 2011 
carbamazepine 
epoxide 
-131 - 100 99 Huerta-Fontela et 
al., 2011 
furosemide 100 >99 Huerta-Fontela et 
al., 2011 
naproxen 90 - 100 100 Boyd et al., 2003 
*- one outlier value (-6.9%) omitted 
 
 
Figure 15. Possible reaction intermediates formed by reaction of carbamazepine with 
chlorine (Taken from Kotcharaksa, 2008) 
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4.4. Passive samplers 
 
Passive sampling can provide TWA concentrations of compounds over deployment 
periods of several weeks, but measure only the freely dissolved material, and not that 
bound to organic and inorganic suspended matter and dissolved organic carbon.  
Where there is limited binding, then the concentrations measured by passive 
sampling should be in agreement with those measured in frequent spot samples of 
water. Where spot samples are taken infrequently, then there may be a difference 
between the estimates of concentration provided by the two methods when the 
concentration in the water fluctuates in time. Where sampling rates of the passive 
samplers are high (up to tens of litres per day, as found in some samplers for non-
polar organic compounds) then this technology can provide estimates of 
concentrations that fall below the limit of detection of routine small volume (less than 
5 L) spot sampling methods. 
 
In this study, the low sampling rates achieved by the passive samplers reduced the 
utility of the estimates of concentrations of some of the pharmaceuticals, and resulted 
in an inability to detect concentrations below the limit of detection of spot sampling.  
For some determinands, apparent contamination of field blanks was an issue 
meaning that these data could not be used. However, for a number of compounds 
where blanks were deemed acceptable and where it was possible to derive 
calibration data for the samplers, it was possible to estimate TWA  concentrations at 
the sites. There was however significant disagreement between the spot sampling 
data and the TWA results which is most likely due to large uncertainties around the 
calibration results. Where the two methods are in agreement it gives some 
reassurance that the spot samples are providing representative information of 
exposures over time.  
 
Overall, the passive sampling data indicate that much more development work is 
required on these types of systems before they can be used routinely in monitoring of 
drinking water. Any future work should probably focus on the development of 
systems that can be installed into treatment plants and which achieve high rates of 
sampling, thus overcoming the calibration uncertainties that were observed in this 
study. 
4.5. Implications for human health 
 
In the previous DWI-funded project, predictions of exposure were compared to 
therapeutic dose values in order to identify pharmaceuticals that may pose a risk to 
human health. Only ten compounds or classes of compounds had therapeutic dose 
concentrations within three orders of magnitude of the exposure predictions (the 
margin of exposure considered by Watts et al., 2007 to be of potential concern), 
these included the non steroidal anti-inflammatory drugs and cocaine.  
 
When  the measured concentrations obtained in the current study are used to refine 
the margins of exposure obtained in the previous project, margins of exposure are 
significantly increased compared to the previous study (Table 12). These results are 
re-assuring and indicate that the study pharmaceuticals (and probably 
pharmaceuticals in general) present in drinking water in England pose no appreciable 
risk to human health. 
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Table 12 Comparison of margins of exposure obtained in this study (from maximum 
concentrations in spot samples) with margins of exposure calculated in the previous 
DWI-funded prioritisation study (Watts et al., 2007) 
 Watts et al., 
2007 (ng/l) 
MoE Maximum 
concentration 
in treated 
water 
(ng/l) 
 
Treated water 
MoE (based 
on maximum 
concentration) 
atenolol 8360 5.98 x 10
3
 <2 >2.50 x 10
7
 
benzoylecgonine - - 3.51 - 
caffeine - - 79.3 
 
- 
carbamazepine 23 1.7 x 10
7
 148 2.64 x 10
6
  
carbamazepine 
epoxide 
- - 16.6 - 
cocaine 2530 395 <5 >2.00 x 10
5
 
cyclophosphamide - - <1 - 
diclofenac 5000 1.50 x 10
4
 <10 >7.50 x 10
6
 
fluoxetine 88.2 2.27 x 10
5
 <5 >4.00 x 10
6
 
ibuprofen 18920 1.06 x 10
4
 3.07 6.5 x 10
7
 
furosemide 5270 3.79 x 10
3
 <5 >4.00 x 10
6
 
ketoprofen 230 4.45 x 10
5
 <1 >1.02 x 10
8
 
naproxen 6330 7.89 x 10
4
 2.72 1.83 x 10
8
 
norfluoxetine - - <10 - 
orlistat 1540 7.80 x 10
4
 <10 >1.20 x 10
7
 
simvastatin 3240 1.54 x 10
3
 <50 >1.00 x 10
5
 
trimethoprim 1270 7.90 x 10
4
 <5 >2.01 x 10
7
 
4.6. Conclusions 
 
This study was performed to determine the potential level of exposure of 
pharmaceuticals in source waters and treated drinking waters in England. The study 
measured a range of pharmaceuticals and illicit drugs at four sites over a 12 month 
period. Generally results agreed with similar studies that have been done elsewhere 
and showed that concentrations of pharmaceuticals and illicit drugs in English 
surface waters are at levels in the below 1 µg/l. Concentrations of pharmaceuticals 
and drugs in drinking waters are generally significantly lower than seen in surface 
waters indicating that the treatment systems in use in England and Wales are 
effective at removing these contaminants. Comparison of measured concentrations 
of the study compounds in drinking waters with information on therapeutic doses 
demonstrated that levels of these compounds in drinking water in England are many 
orders of magnitude lower than levels that are given to patients therapeutically. It 
would therefore appear that the presence of low levels of pharmaceuticals and illicit 
drugs in drinking waters in England and Wales do not pose an appreciable risk to 
human health. 
4.7. Recommendations 
 
During the study, a number of areas have been identified that are worthy of further 
study, namely: 
 
 The application of more complex modelling approaches for estimating the 
concentrations of pharmaceuticals in surface waters – It is clear from this study 
that the simple models used in risk assessment do not always provide good 
estimates of exposure. By applying more complex models that consider 
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fluctuations in pharmaceutical use in a catchment, catchment hydrology and the 
potential for a compound to dissipate in different environmental compartments, it 
may be possible to better identify those pharmaceuticals that pose the greatest risk 
to the environment and to human health. 
 
 More detailed evaluation of the toxicological risks of pharmaceuticals in drinking 
water – In this study and the previous study, a very simple approach was used to 
establish whether levels of pharmaceuticals in the environment are of concern to 
human health or not. While the assessment are re-assuring and indicate that levels 
are much lower than levels where toxicological effects would be seen, it would be 
worthwhile to perform a much more thorough evaluation of the available data on 
the effects of pharmaceuticals on human health. Such a study should recognise 
that  the exposure will be long-term and that consumers will be exposed to a 
mixture of substances in their drinking water. 
  
 Assessment of the potential for transformation products to be formed in drinking 
water treatment – The data for carbamazepine epoxide indicate that in some 
instances, drinking water treatment processes can convert one substance to 
another substance which may be of concern. It would be worthwhile to develop a 
better understanding of the mechanisms of removal of pharmaceuticals in different 
drinking water treatment processes and of the potential for compounds to be 
formed which may be of toxicological concern. 
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APPENDIX A: CONSOLIDATED LIST OF PHARMACEUTICALS (AND METABOLITES) IDENTIFIED IN DIFFERENT PRIORITISATION 
EXERCISES OF RELEVANCE TO DRINKING WATER 
 
Molecule Class PEC Reason Monitored/ 
Detected 
Metabolite Prioritisation 
acamprosate alcoholism treatment 648 low exposure:dose   1 
allopurinol antigout 150 High PEC  oxypurinol 2 
aminophylline muscle relaxant 2310 low exposure:dose   1 
amiodarone amiodarone 555 high Kow, adverse effects linked to 
iode CYP-450 and P-gp inhibitor 
 N-desethyl amiodarone 2 
amoxicillin antibiotic 6847 High PEC Y  2,4 
amphetamine illegal drug 5270 low exposure:dose   2 
amphotocerin B antifungal 415 High PEC, kidney toxicity   2 
atorvastatin lipid lowering agent - - Y  1,3 
atenolol -blocker 419 High PEC Y  2,3,4 
beclometasone anti-asthmatic 728 low exposure:dose   1 
bendroflumethiazide dicuretic 224 low exposure:dose   1 
bezafibrate lipid lowering agent 476 High PEC, muscular disease, PPAR 
agonist 
Y  2,4 
buflomedil anti-eschemic 291 High PEC   2 
carbamazepine anticonvulsant 765 High PEC, P450 inducer Y 10,11-
epoxycarbamazepine 
2,3,4 
ceftriaxone antibiotic 315 High PEC   2 
ciclosporin immunosupression 550 low exposure:dose   1 
ciprofloxacin antibiotic 139 High PEC Y  2,4 
clarithromycin antibiotic 62 CYP-450 and P-gp inhibitor Y  2 
codeine analgesic 3240 low exposure:dose Y  1,4 
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Molecule Class PEC Reason Monitored/ 
Detected 
Metabolite Prioritisation 
cyamemazine antipsychotic 124 endocrine and metabolic disorders   2 
diamorphine illegal drug 130 low exposure:dose   2 
diazepam tranquilizer - - Y  3,4 
diclofenac NSAID 35 adverse effects on kidney Y  1,2,3,4 
diosmin vitaminic P 8528 potent estrogen  deglycosylated diosmin 2 
doxazosin -blocker 88 low exposure:dose   1 
doxycycline antibiotic 103 High PEC Y  2,4 
enalapril ACE inhibitor - - Y  3,4 
ecstasy illegal drug 1075 low exposure:dose   1 
ethinylestradiol contraceptive - - Y  3 
fluoxetine SSRI 9 serotonin receptor agonist, P-gp 
inhibitor 
Y norfluoxetine 2,3,4 
fosfomycin antibiotic 155 High PEC   2 
furosemide diuretic 486 High PEC, low exposure:dose Y  1,2,4 
gemfibrozil antilipidemic - - Y  3,4 
ibuprofen NSAID 1370 Potential renal toxicity Y 2-OH-ibuprofen, 
carboxy-ibuprofen 
1,2,4 
ketoprofen NSAID 421 Potential renal toxicity Y  1,2 
losartan ATH sartan 334 Decrease in aldosterone secretion  5-carboxylic acid 
metabolite 
2 
lisinopril agiotensin converting 
enzyme inhibitor 
2240 low exposure:dose   1 
LSD illegal drug 3350 low exposure:dose   1 
meprobamate anti-anxiety agent - - Y  3 
metformin antidiabetic 15367 High PEC Y  2,4 
51 
 
 
Molecule Class PEC Reason Monitored/ 
Detected 
Metabolite Prioritisation 
methadone opioid agonist 94.4 low exposure:dose   1 
methylbenzoylecgonine illegal drug 2530 low exposure:dose Y  1 
metronidazole antiprotozoal 150 High PEC  OH-metronidazole 2 
naftidrofuryl anti-eschemic 1039 serotoninergic 5-HT2 receptor 
agonist 
  2 
naproxen NSAID 597 Potential renal toxicity Y  1,2,3,4 
nitroglycerin vasodilator 1040 low exposure:dose   1 
ofloxacin antibiotic 94 High PEC Y  2 
norethisterone progesterone 
derivative 
251 low exposure:dose   1 
oxazepam benzodiazepine 207 High PEC Y  2,4 
paracetamol antipyretic/analgesic 64101 High PEC Y  2,4 
piperacillin piperacillin 102 High PEC   2 
pravastatin lipid lowering agent 125 Adverse effects on muscles, 
carcinogenic effects in rodents 
  2 
prednisolone corticoid 85 immunomodulating effects Y  2 
pristinamycin antibiotic 910 High PEC   2 
propranolol -blocker 68 Adverse effects on thyroid Y 4-OH-propanolol 2 
ramipril diuretic 9370 low exposure:dose   1 
ranitidine antacid 133 High PEC Y  2,4 
sertraline SSRI 20 Serotoninergic activity, P450 inhibitor Y  2 
simvastatin lipid lowering agent 75.4 low exposure:dose N  1,2,4* 
sulfamethoxazole antibiotic 153 High PEC Y acetylsulfamethoxazole 2,3,4 
tetrahydrocannabinol illegal drug 9740 low exposure:dose   1 
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Molecule Class PEC Reason Monitored/ 
Detected 
Metabolite Prioritisation 
tramadol analgesic 177 High PEC Y demethyltramadol 2 
trimethoprim antibiotic 38 High PEC Y  2,3,4 
valproic acid anticonvulsant 1357 P450 inhibitor   2,4 
vancomycin antibiotic 21    2 
zidovudine anti-viral 648 low exposure:dose   1 
 
Metabolite Parent compound Reason PEC Monitored Prioritisation 
salicylic acid aspirin active metabolite - Y 2 
fenofibric acid fenofibrate active metabolite 1148 Y 2 
perindoprilat pendopril active metabolite 192  2 
ramiprilat ramipril active metabolite 125  2 
demethyltramadol tramadol active, high excretion rate 355  2 
hydroxy-ibuprofen ibuprofen high excretion rate 1370 Y 2 
carboxy-ibuprofen carboxy-ibuprofen high excretion rate 2027 Y 2 
acetyl-sulfamethoxazole sulfamethoxazole high excretion rate 229 Y 2 
14-OH-clarithromycin clarithromycin active metabolite 52  2 
norfluoxetine fluoxetine active, high excretion rate 24 N 2,3,4 
OH-metronidazole metronidazole active, high excretion rate 234  2 
-hydroxy-acid-metabolite simvastatin active metabolite 87 N 2,3,4 
2-OH-atorvastatin atorvastatin active metabolite - N 2,3 
4-OH-atorvastatin atorvastatin active metabolite - N 2,3 
1- Watts and Crane (2007); 2 - Besse and Garric (2008); 3 – US Monitoring list; 4 – Global Water Research Coalition (2008); *- metabolite 
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APPENDIX B – SPOT SAMPLING DATA (VALUES ARE EXPRESSED IN NG/L AND ARE MEANS OF THREE REPLICATE SAMPLES) 
 
Table B1. Concentration of atenolol in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4   
 RW  TW RW  TW RW  TW RW  TW 
 Mean SD  Mean SD  Mean SD  Mean SD Mean 
Sept 36.90 0.75 <LOD 64.50 1.56 <LOD 11.70 0.17 <LOD 21.37 0.65 <LOD 
Oct 38.47 0.32 <LOD 58.90 1.10 <LOD 31.65 1.35 <LOD 113.68 2.96 <LOD 
Nov 58.93 1.05 <LOD 66.64 2.22 <LOD 67.56 1.59 <LOD 74.52 6.43 <LOD 
Dec 35.84 0.62 <LOD 46.72 0.62 <LOD 40.33 0.37 <LOD 25.93 0.24 <LOD 
Jan 57.55 1.08 <LOD 91.17 0.68 <LOD 15.32 <LOD NS 25.32 0.84 <LOD 
Feb 66.34 0.31 <LOD NS - NS 21.37 <LOD NS 23.35 0.51 <LOD 
Mar 64.73 0.18 <LOD 57.60 0.44 <LOD NS <LOD NS 19.62 0.58 <LOD 
Apr 53.19 0.59 <LOD 46.49 0.43 <LOD NS <LOD NS 24.02 1.01 <LOD 
May 38.84 0.51 <LOD 52.04 1.57 <LOD 45.97 2.28 <LOD 24.06 0.23 <LOD 
Jun_1 40.54 0.38 <LOD 41.51 1.52 <LOD NS <LOD NS 48.83 0.70 <LOD 
Jun_2/Jul_1 36.31 0.26 <LOD 54.04 1.11 <LOD 13.34 0.62 <LOD 23.42 0.93 <LOD 
Jul_2 23.04 0.61 <LOD 39.64 0.92 <LOD 8.18 0.37 <LOD 66.80 0.41 <LOD 
Aug 18.13 0.57 <LOD 31.2 0.6 <LOD 12.0 0.8 <LOD 43.74 0.79 <LOD 
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Table B2. Concentration of benzoylecgonine in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4    
 RW  TW RW  TW RW  TW RW  TW  
 Mean SD  Mean SD  Mean SD  Mean SD Mean SD 
Sept 1.30 0.10 <LOD 4.17 0.12 <LOD 2.30 0.10 <LOD 9.97 0.23 2.27 0.06 
Oct 1.30 0.00 <LOD 4.67 0.15 <LOD 3.85 0.07 <LOD 15.59 0.47 3.02 0.13 
Nov 1.20 0.04 <LOD 4.19 0.06 <LOD 3.96 0.16 <LOD 11.37 2.77 3.51 0.14 
Dec 0.97 0.03 <LOD 2.42 0.10 <LOD 1.25 0.03 <LOD 3.32 0.08 <LOD <LOD 
Jan <LOD - <LOD 2.75 0.10 <LOD 2.72  NS 2.09 0.06 <LOD <LOD 
Feb <LOD - <LOD NS - NS 2.70  NS 3.13 0.13 <LOD <LOD 
Mar <LOD - <LOD  0.01 <LOD NS 0.10 NS 1.99 0.06 <LOD <LOD 
Apr <LOD - <LOD  0.33 <LOD NS 0.18 NS 3.60 0.21 1.12 0.03 
May 1.00 0.02 <LOD 5.77 0.22 <LOD 4.80 0.29 <LOD 9.80 0.08 1.59 0.06 
Jun_1 1.66 0.07 <LOD 3.48 0.10 <LOD NS - NS 10.06 0.07 2.64 0.26 
Jun_2/Jul_1 2.06 0.10 <LOD 4.22 0.16 <LOD 2.02 0.11 <LOD 7.21 0.07 1.98 0.09 
Jul_2 1.67 0.06 <LOD 2.39 0.14 <LOD 2.98 0.15 <LOD 16.28 0.13 3.34 0.02 
Aug 1.75 0.03 <LOD 1.98 0.06 <LOD 2.97 0.10 <LOD 11.48 0.46 3.34 0.08 
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Table B3. Concentration of caffeine in spot samples obtained during the study 
 Site 1    Site 2    Site 3    Site 4    
 RW  TW  RW  TW  RW  TW  RW  TW  
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Sept 441.00 17.00 79.33 2.31 95.00 3.00 46.33 10.69 81.90 5.42 8.16 1.84 236.09 12.11 14.57 1.45 
Oct 95.17 0.32 7.60 0.40 67.77 1.79 3.63 0.68 141.08 0.87 <LOD - 149.59 0.65 <LOD - 
Nov 175.53 3.85 7.56 0.15 186.56 23.98 3.38 0.14 198.76 15.44 4.22 0.14 329.06 45.78 14.78 1.27 
Dec 260.58 12.79 21.07 4.69 99.25 4.62 11.22 0.07 119.77 0.49 7.66 0.11 226.58 6.52 11.60 0.58 
Jan 287.06 11.47 20.76 0.73 224.25 6.61 11.42 2.95 68.82 3.04 NS - 279.49 11.51 13.47 0.23 
Feb 234.51 3.81 21.79 1.92 NS - NS - 104.08 4.66 NS - 201.85 13.87 10.10 0.18 
Mar 232.35 2.12 19.87 2.43 103.56 1.14 11.17 0.27 NS - NS - 211.55 5.00 2.88 0.26 
Apr 221.60 3.36 18.13 0.96 125.21 0.74 9.36 0.34 NS - NS - 241.25 7.56 14.55 0.21 
May 162.69 2.74 12.44 0.27 91.66 0.77 5.98 0.25 163.05 15.13 2.82 0.13 284.98 6.20 10.35 0.67 
Jun_1 108.02 3.00 12.18 0.09 82.08 3.17 8.14 1.17 NS - NS - 267.35 5.40 12.03 0.22 
Jun_2/Jul_1 140.09 4.75 15.68 0.70 92.63 4.78 10.03 0.37 54.74 3.06 3.00 0.46 82.22 1.77 29.22 22.62 
Jul_2 129.71 2.11 14.87 0.11 63.70 2.17 3.05 0.20 100.22 3.58 3.88 0.32 149.59 2.84 17.40 0.69 
Aug 86.65 3.99 14.77 1.14 70.94 1.40 5.65 0.21 95.88 3.85 8.83 2.03 142.25 2.45 17.40 0.07 
 
56 
 
Table B4. Concentration of carbamazepine in spot samples obtained during the study 
 Site 1    Site 2    Site 3    Site 4    
 RW  TW  RW  TW  RW  TW  RW  TW  
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Sept 86.33 0.58 9.0 0.0 175.3 3.2 20.7 0.6 346.13 6.31 1.07 0.06 215.17 7.97 2.37 0.12 
Oct 111.53 0.67 8.4 0.2 202.5 2.9 17.6 4.3 146.93 2.66 1.00 0.05 392.67 7.36 1.31 0.06 
Nov 124.50 2.35 11.5 0.3 138.6 2.5 148.2 2.1 364.29 9.50 0.96 0.06 185.07 8.51 1.37 0.03 
Dec 58.50 0.47 11.0 0.3 46.6 0.2 3.1 0.0 75.52 0.86 1.25 0.02 37.14 0.17 1.03 0.07 
Jan 58.64 0.07 11.9 0.2 70.0 1.1 4.8 2.7 34.34 0.01 NS - 25.24 0.58 <LOD - 
Feb 49.40 0.64 11.5 0.2 NS - NS  42.34 0.56 NS - 29.00 0.92 <LOD - 
Mar 59.91 0.80 11.8 0.1 45.0 0.1 2.7 0.0 NS - NS - 16.39 0.28 <LOD - 
Apr 62.47 0.27 11.3 0.1 53.9 0.6 2.2 0.1 NS - NS - 34.03 0.19 <LOD - 
May 78.9 1.76 12.0 0.3 100.4 2.3 2.0 0.1 163.47 3.41 <LOD - 106.00 1.43 <LOD - 
Jun_1 128.0 2.89 13.8 0.3 139.7 3.6 2.2 0.0 NS - NS - 231.36 4.00 0.97 0.06 
Jun_2/Jul_1 135.33 2.65 16.5 0.4 167.7 4.7 3.7 0.05 471.45 12.40 <LOD - 289.66 3.05 1.73 0.06 
Jul_2 198.9 6.6 17.3 0.1 249.40 13.67 1.22 0.05 523.22 9.01 <LOD - 480.19 12.64 3.96 0.09 
Aug 194.40 7.16 16.6 0.2 277.00 5.39 1.59 0.08 555.29 8.00 <LOD - 331.62 8.03 3.96 0.09 
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Table B5. Concentration of carbamazepine epoxide in spot samples obtained during the study 
 Site 1    Site 2    Site 3    Site 4    
 RW  TW  RW  TW  RW  TW  RW  TW  
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Sept 11.33 0.58 6.00 0.00 19.67 0.58 7.00 0.00 24.70 1.66 4.90 0.10 16.67 0.51 10.73 0.06 
Oct 10.90 0.17 4.23 0.06 19.30 0.26 8.13 0.35 15.97 0.62 5.03 0.22 14.95 0.74 8.16 0.11 
Nov 7.58 0.83 3.65 0.10 7.22 1.22 16.60 0.85 13.99 1.29 6.01 0.15 9.91 0.32 8.74 0.65 
Dec 4.17 0.08 3.41 0.07 3.25 0.04 4.04 0.09 3.88 0.07 4.29 0.19 1.93 0.06 3.04 0.10 
Jan 3.88 0.19 2.76 0.12 4.97 0.13 3.03 0.17 1.99 0.04  NS -  1.12 0.10 2.15 0.02 
Feb 2.83 0.10 2.27 0.12  NS -  NS  -  0.50    NS -  1.41 0.32 1.93 0.13 
Mar 3.46 0.09 2.95 0.16 3.18 0.15 3.02 0.07  NS -   NS -  0.50   0.50   
Apr 3.09 0.15 2.92 0.09 2.47 0.04 2.88 0.09  NS -  NS  -  1.33 0.01 3.08 0.03 
May 4.25 0.13 3.89 0.06 5.48 0.51 3.85 0.03 6.26 0.13 2.53 0.04 4.32 0.05 4.46 0.02 
Jun_1 6.53 0.19 4.64 0.08 7.79 1.12 4.70 0.10  NS -  NS  -  7.62 0.13 6.24 0.12 
Jun_2/Jul_1 7.50 0.25 5.31 0.08 9.75 0.29 7.92 0.22 14.75 0.39 0.50   10.59 0.36 9.30 0.03 
Jul_2 9.48 0.29 6.10 0.09 12.03 0.22 5.28 0.20 13.52 0.64 3.63 0.11 13.84 0.30 9.94 0.15 
Aug 8.62 0.25 5.77 0.15 11.22 0.16 5.15 0.14 12.90 0.40 4.61 0.12 10.60 0.24 9.94 0.18 
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Table B6. Concentration of diclofenac in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4   
 RW  TW RW  TW RW  TW RW  TW 
 Mean SD Mean Mean SD Mean Mean SD Mean Mean SD Mean 
Sept <LOD - <LOD 27.33 0.58 <LOD 14.30 0.95 <LOD 17.57 0.38 <LOD 
Oct 20.17 0.15 <LOD 34.23 0.65 <LOD 50.00 7.85 <LOD 47.14 2.32 <LOD 
Nov 24.33 3.00 <LOD 33.86 11.11 <LOD 76.29 3.64 <LOD 44.26 4.64 <LOD 
Dec <LOD - <LOD 12.48 0.32 <LOD 18.86 1.89 <LOD 10.56 0.46 <LOD 
Jan 20.82 0.86 <LOD 38.99 0.95 <LOD <LOD n/a NS 12.60 0.83 <LOD 
Feb 17.76 2.21 <LOD NS - NS 10.84 0.68 NS 17.28 1.52 <LOD 
Mar 11.00 0.20 <LOD 10.35 0.71 <LOD NS - NS <LOD - <LOD 
Apr <LOD - <LOD 11.15 0.13 <LOD NS - NS <LOD - <LOD 
May <LOD - <LOD 15.69 1.79 <LOD 15.13 1.44 <LOD 11.93 1.50 <LOD 
Jun_1 <LOD - <LOD 10.54 1.29 <LOD NS - NS <LOD - <LOD 
Jun_2/Jul_1 <LOD - <LOD <LOD - <LOD <LOD n/a <LOD <LOD - <LOD 
Jul_2 <LOD - <LOD <LOD - <LOD <LOD n/a <LOD 13.39 0.43 <LOD 
Aug <LOD - <LOD 12.10 0.74 <LOD <LOD n/a <LOD 11.56 0.50 <LOD 
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Table B7. Concentration of furosemide in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4   
 RW  TW RW  TW RW  TW RW  TW 
 Mean SD Mean Mean SD Mean Mean SD Mean Mean SD Mean 
Sept  <LOD -  <LOD  15.77 1.05  <LOD  <LOD <LOD  <LOD  8.23 1.55 <LOD  
Oct 12.40 1.32  <LOD 21.20 0.12 <LOD  5.30 0.45  <LOD 47.48 3.17  <LOD 
Nov 21.09 0.70  <LOD 39.42 0.07  <LOD 35.95 3.90  <LOD 63.48 11.86  <LOD 
Dec 15.42 1.04  <LOD 26.00 1.52  <LOD 22.98 0.93  <LOD 15.62 1.20  <LOD 
Jan 28.90 0.82  <LOD 43.10 2.38  <LOD 6.92 1.31  NS 16.99 0.13  <LOD 
Feb 17.42 1.66  <LOD  NS -  NS  9.55 0.44  NS 16.89 2.92  <LOD 
Mar 12.62 0.17  <LOD 23.68 0.69  <LOD  NS -   NS <LOD  -   <LOD 
Apr 6.44 0.39  <LOD 17.04 0.57  <LOD  NS -  NS  <LOD -   <LOD 
May  <LOD -   <LOD 9.48 0.39  <LOD 0.40 0.40  <LOD 5.34 0.34  <LOD 
Jun_1  <LOD -   <LOD 7.56 0.47  <LOD  NS NS  NS  19.54 0.55  <LOD 
Jun_2/Jul_1 5.42 0.11  <LOD <LOD -   <LOD <LOD  -   <LOD <LOD  -  <LOD  
Jul_2  <LOD -   <LOD 6.59 1.73  <LOD  <LOD -   <LOD 12.38 0.97  <LOD 
Aug  <LOD -   <LOD 8.05 0.35  <LOD  <LOD -   <LOD 13.25 1.67  <LOD 
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Table B8. Concentration of ibuprofen in spot samples obtained during the study 
 Site 1    Site 2   Site 3   Site 4   
 RW  TW  RW  TW RW  TW RW  TW 
 Mean SD Mean SD Mean SD Mean Mean SD Mean Mean SD Mean 
Sept 6.33 0.58 <LOD - 10.00 1.00 <LOD <LOD <LOD <LOD 9.30 1.39 <LOD 
Oct 12.03 0.47 <LOD - 5.57 0.29 <LOD 8.17 1.41 <LOD 11.56 1.43 <LOD 
Nov 20.67 0.56 <LOD - 19.65 1.65 <LOD 21.54 3.19 <LOD 38.15 7.49 <LOD 
Dec 21.63 0.53 <LOD - 10.46 0.50 <LOD 10.91 0.66 <LOD 15.14 0.21 <LOD 
Jan 28.45 1.47 3.07 0.19 38.41 3.30 <LOD 5.37 0.51 NS 26.32 2.17 <LOD 
Feb 27.14 1.64 <LOD - NS - NS 11.79 0.70 NS 22.95 2.14 <LOD 
Mar 30.84 2.54 <LOD - 16.42 1.41 <LOD NS - NS 24.65 2.67 <LOD 
Apr 25.70 1.86 <LOD - 15.66 1.65 <LOD NS - NS 21.61 0.76 <LOD 
May 19.36 2.21 <LOD - 10.47 0.37 <LOD 21.01 2.18 <LOD 26.68 2.54 <LOD 
Jun_1 8.58 0.39 <LOD - 5.75 1.22 <LOD NS - NS 17.14 1.98 <LOD 
Jun_2/Jul_1 9.49 0.74 <LOD - 5.27 0.05 <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Jul_2 11.09 0.87 <LOD - 3.40 0.17 <LOD <LOD <LOD <LOD 15.59 1.54 <LOD 
Aug 7.52 0.60 <LOD - <LOD - <LOD 2.44 0.85 1.00 7.03 0.34 <LOD 
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Table B9. Concentration of naproxen in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4    
 RW  TW RW  TW RW  TW RW  TW  
 Mean SD  Mean SD  Mean SD  Mean SD Mean SD 
Sept 15.0 1.00 <LOD 17.0 1.00 <LOD 15.07 1.36 <LOD 23.57 0.76 2.47 0.21 
Oct 22.5 0.21 <LOD 18.9 0.76 <LOD 18.11 0.57 <LOD 41.13 1.73 2.72 0.99 
Nov 23.9 0.92 <LOD 20.6 0.42 <LOD 28.94 4.21 <LOD 44.35 5.35 2.55 0.13 
Dec 17.3 0.19 <LOD 13.6 0.09 <LOD 17.03 0.50 <LOD 11.59 0.70 <LOD - 
Jan 25.6 0.18 <LOD 42.2 0.81 <LOD 4.85 0.69 NS 13.28 0.39 <LOD - 
Feb 20.3 0.51 <LOD NS  NS 8.53 0.65 NS 13.90 2.14 <LOD - 
Mar 26.4 0.92 <LOD 28.7 0.58 <LOD NS NS NS 11.08 0.51 <LOD - 
Apr 20.0 0.90 <LOD 18.5 0.32 <LOD NS NS NS 12.83 0.21 <LOD - 
May 16.1 0.35 <LOD 20.0 1.16 <LOD 17.55 1.76 <LOD 22.61 0.25 <LOD - 
Jun_1 10.2 0.25 <LOD 11.4 0.59 <LOD NS NS NS 21.70 0.90 <LOD - 
Jun_2/Jul_1 13.1 0.83 <LOD 9.8 0.26 <LOD 7.77 0.45 <LOD 12.53 0.68 <LOD - 
Jul_2 13.1 0.32 <LOD 6.9 0.29 <LOD 9.70 0.39 <LOD 43.40 1.00 <LOD - 
Aug 13.1 0.84 <LOD 9.5 0.05 <LOD 8.72 0.33 <LOD 28.69 0.98 <LOD - 
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Table B10. Concentration of trimethoprim in spot samples obtained during the study 
 Site 1   Site 2   Site 3   Site 4   
 RW  TW RW  TW RW  TW RW  TW 
 Mean SD Mean Mean SD Mean Mean SD Mean Mean SD Mean 
Sept 11.00 0.00 <LOD  13.77 0.06  <LOD <LOD  -  <LOD  <LOD  -  <LOD  
Oct 12.13 0.29  <LOD 11.43 0.59  <LOD  <LOD -   <LOD 9.27 0.51  <LOD 
Nov 6.10 0.10  <LOD 5.45    <LOD 7.74 0.46  <LOD 5.93 -   <LOD 
Dec <LOD   -  <LOD  <LOD -   <LOD  <LOD -   <LOD  <LOD -   <LOD 
Jan 8.60 0.30  <LOD 10.00 0.08  <LOD  <LOD -   NS  <LOD -   <LOD 
Feb 7.12 0.14  <LOD NS -  NS   <LOD -   NS 6.18 0.52  <LOD 
Mar 11.86 0.32  <LOD 8.98 0.14  <LOD  NS -  NS   <LOD -   <LOD 
Apr 11.05 0.13  <LOD 7.40 0.32  <LOD  NS -  NS  6.06 0.21  <LOD 
May 13.80 0.50  <LOD 10.82 0.93  <LOD 7.77 0.43  <LOD 5.92 0.05  <LOD 
Jun_1 13.80 0.50  <LOD 12.38 2.18  <LOD  NS -  NS  19.48 0.38  <LOD 
Jun_2/Jul_1 10.19 0.72  <LOD 10.82 0.60  <LOD 8.27 0.72  <LOD 11.11 0.38  <LOD 
Jul_2 12.85 1.40  <LOD 13.30 2.01  <LOD  <LOD -   <LOD 26.42 0.38  <LOD 
Aug 8.91 1.07  <LOD 7.56 0.72  <LOD  <LOD -   <LOD 15.89 1.42  <LOD 
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APPENDIX C. PASSIVE SAMPLER MASS DATA 
 
Table C1. Mass (ng) of pharmaceuticals recovered in the receiving phase of the deployed Chemcatcher samplers for Site 1. Values for raw 
water (RW) and treated water (TW) are means of three replicates. Only one sample blank was used. Underlined values are indicative values 
only. 
 Feb 
/Mar 
  Mar 
/Apr 
  Apr 
/May 
  May 
/Jun 
  Jun   Jun 
/Jul 
  Jul 
/Aug 
  
 blan
k 
RW TW blank RW TW blank RW TW blank RW TW blank RW TW blan
k 
RW TW blank RW TW 
atenolol <1 23.1 <1 <1 4.5 <1 <1 3.3 <1 <1 13.2 <1 <2 11.5 <2 <1 10.7 <1 <1 4.6 <1 
benzoylecgonine <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 
caffeine 15.6 61.5 8.97 21.3 34.4 13.1 1.4 15.7 6.2 0.8 24.0 3.2 1.2 29.2 3.9 4.2 16.0 6.1 3.9 13.3 10.8 
carbamazepine <1 47.0 3.2 <1 8.3 3.1 <1 6.7 7.7 <1 75.2 5.5 <1 103 9.0 2.0 195 14.8 <1 118 21.2 
cocaine <2 <2 <2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <2 <2 <2 <1 <1 <1 1.3 <1 <1 
diclofenac <1 8.3 <1 <1 1.8 <1 <5 <5 <5 <5 2.7 <5 <5 4.2 <5 <1 4.0 <1 0.9 3.4 <1 
fluoxetine 2.3 0.6 0.9 0.3 <5 0.2 <2 <2 <2 <1 1.1 <1 <5 <5 <5 1.8 2.0 2.7 7.6 0.8 3.0 
furosemide <1 13.2 <1 <1 1.7 <1 <1 1.1 <1 <1 2.1 <1 <2 2.6 <2 <5 2.0 <5 <1 0.8 <1 
ibuprofen <1 17.6 <1 <1 2.8 <1 <1 3.1 <1 <2 9.0 <2 <1 7.6 <1 <1 6.0 <1 <1 2.7 <1 
ketoprofen <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 
naproxen <1 16.3 <1 <1 3.9 <1 <1 2.7 <1 <1 7.2 <1 <1 8.5 <1 <1 6.7 <1 <1 4.6 <1 
norfluoxetine 10.3 <5 6.7 1.7 <10 0.9 <2 <2 <2 <5 <5 <5 <5 <5 <5 3.0 <5 2.6 6.9 2.4 3.6 
trimethoprim 0.5 8.8 0.1 0.5 3.9 <1 <1 2.8 <1 <1 10.6 <1 <1 7.3 <1 <5 19.0 <5 2.7 9.1 <2 
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Table C2. Mass (ng) of pharmaceuticals recovered in the receiving phase of the deployed Chemcatcher samplers for Site 3. Values for raw 
water (RW) and treated water (TW) are means of three replicates. Only one sample blank was used. Underlined values are indicative values 
only. 
 May/Jun   Jun/Jul   Jul/Aug   
 blank RW TW blank RW TW blank RW TW 
atenolol <1 <1 <1 <1 <1 <1 <1 <1 <1 
benzoylecgonine <1 <1 <1 <1 <1 <1 <1 <1 <1 
caffeine <2 3.3 2.8 <2 3.2 1.7 <5 9.9 2.1 
carbamazepine <1 0.8 8.6 <1 7.9 <1 <1 13.9 <1 
cocaine <1 <1 <1 <1 <1 <1 <1 <1 <1 
diclofenac <5 <5 <5 <2 <2 <2 <1 <1 <1 
fluoxetine <2 <2 <2 1.84 <1 2.4 <1 0.8 <1 
furosemide <2 <2 <2 <2 <2 <2 <1 <1 <1 
ibuprofen <1 <1 <1 <1 <1 <1 <1 <1 <1 
ketoprofen <1 <1 <1 <1 <1 <1 <1 <1 <1 
naproxen <1 <1 <1 <1 <1 <1 <1 <1 <1 
norfluoxetine <10 <10 <10 2.4 <2 <2 2.3 <5 <5 
trimethoprim <2 <2 1.2 2.7 <1 <1 <2 <2 <2 
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APPENDIX D: ESTIMATED CONCENTRATIONS FROM CHEMCATCHERS 
 
Table D1.  Mean estimated water concentrations of diclofenac detected in 
Chemcatcher® passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA) SS* 
1 RW 28 Feb/Mar n.d. 14 
1 TW 28 Feb/Mar n.d. n.d. 
1 RW 28 Mar/Apr 63 11 
1 TW 28 Mar/Apr n.d. n.d. 
1 RW 28 Apr/May n.d. n.d. 
1 TW 28 Apr/May n.d. n.d. 
1 RW 29 May/Jun n.d. n.d. 
1 TW 29 May/Jun n.d. n.d. 
1 RW 23 Jun 96 n.d. 
1 TW 23 Jun n.d. n.d. 
1 RW 32 Jun/Jul 42 n.d. 
1 TW 32 Jun/Jul n.d. n.d. 
1 RW 28 Jul/Aug 56 n.d. 
1 TW 28 Jul/Aug n.d. n.d. 
2 RW 28 May/Jun n.d. 15
c
 
2 TW 28 May/Jun n.d. n.d. 
2 RW 32 Jun/Jul n.d. n.d. 
2 TW 32 Jun/Jul n.d. n.d. 
2 RW 28 Jul/Aug n.d. n.d. 
2 TW 28 Jul/Aug n.d. n.d. 
*- SPOT SAMPLER DATA ESTIMATED FROM DATA FOR CONSECUTIVE MONTHS 
 
Table D2.  Mean estimated water concentrations of atenolol detected in 
Chemcatcher® passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA)
 
 SS 
1 RW 28 Feb/Mar 118 29 
1 TW 28 Feb/Mar n.d. n.d. 
1 RW 28 Mar/Apr 63 59 
1 TW 28 Mar/Apr n.d. n.d. 
1 RW 28 Apr/May 17 46 
1 TW 28 Apr/May n.d. n.d. 
1 RW 29 May/Jun 65 40 
1 TW 29 May/Jun n.d. n.d. 
1 RW 23 Jun 105 38 
1 TW 23 Jun n.d. n.d. 
1 RW 32 Jun/Jul 48 30 
1 TW 32 Jun/Jul n.d. n.d. 
1 RW 28 Jul/Aug 23 21 
1 TW 28 Jul/Aug n.d. n.d. 
2 RW 28 May/Jun n.d. 46
c
 
2 TW 28 May/Jun n.d. n.d. 
2 RW 32 Jun/Jul n.d. 11 
2 TW 32 Jun/Jul n.d. n.d. 
2 RW 28 Jul/Aug n.d. 10 
2 TW 28 Jul/Aug n.d. n.d. 
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Table D3.  Mean estimated concentration of caffeine detected in Chemcatcher® 
passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA) SS
a
 
1 RW 28 Feb/Mar 234 233 
1 TW 28 Feb/Mar n.d. 21 
1 RW 28 Mar/Apr 122 227 
1 TW 28 Mar/Apr n.d. 19 
1 RW 28 Apr/May 80 192 
1 TW 28 Apr/May 32 15 
1 RW 29 May/Jun 118 123 
1 TW 29 May/Jun 16 12 
1 RW 23 Jun 182 124 
1 TW 23 Jun 24 14 
1 RW 32 Jun/Jul 53 135 
1 TW 32 Jun/Jul 9 15 
1 RW 28 Jul/Aug 68 108 
1 TW 28 Jul/Aug 55 15 
2 RW 28 May/Jun 38 163
c
 
2 TW 28 May/Jun 17 3
c
 
2 RW 32 Jun/Jul 27 77 
2 TW 32 Jun/Jul 10 3 
2 RW 28 Jul/Aug 69 98 
2 TW 28 Jul/Aug n.d. 6 
 
Table D4.  Mean estimated water concentrations of carbamazepine detected in 
Chemcatcher® passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA) SS 
1 RW 28 Feb/Mar 559 55 
1 TW 28 Feb/Mar 38 12 
1 RW 28 Mar/Apr 147 61 
1 TW 28 Mar/Apr 37 12 
1 RW 28 Apr/May 80 71 
1 TW 28 Apr/May 92 12 
1 RW 29 May/Jun 865 103 
1 TW 29 May/Jun 63 13 
1 RW 23 Jun 1485 132 
1 TW 23 Jun 194 15 
1 RW 32 Jun/Jul 2013 167 
1 TW 32 Jun/Jul 133 17 
1 RW 28 Jul/Aug 1403 167 
1 TW 28 Jul/Aug 373 17 
2 RW 28 May/Jun 13 164
c
 
2 TW 28 May/Jun 154 n.d. 
2 RW 32 Jun/Jul 183 502 
2 TW 32 Jun/Jul  15 n.d. 
2 RW 28 Jul/Aug 166 544 
2 TW 28 Jul/Aug n.d. n.d. 
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Table D5.  Mean estimated water concentrations of ibuprofen detected in 
Chemcatcher® passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA) SS 
1 RW 28 Feb/Mar 90 29 
1 TW 28 Feb/Mar n.d. n.d. 
1 RW 28 Mar/Apr 39 28 
1 TW 28 Mar/Apr n.d. n.d. 
1 RW 28 Apr/May 16 192 
1 TW 28 Apr/May n.d. n.d. 
1 RW 29 May/Jun 44 14 
1 TW 29 May/Jun n.d. n.d. 
1 RW 23 Jun 69 13 
1 TW 23 Jun n.d. n.d. 
1 RW 32 Jun/Jul 27 9 
1 TW 32 Jun/Jul n.d. n.d. 
1 RW 28 Jul/Aug 14 9 
1 TW 28 Jul/Aug n.d. n.d. 
2 RW 28 May/Jun n.d. 21
c
 
2 TW 28 May/Jun n.d. n.d. 
2 RW 32 Jun/Jul n.d. n.d. 
2 TW 32 Jun/Jul n.d. 3 
2 RW 28 Jul/Aug n.d. 2 
2 TW 28 Jul/Aug n.d. n.d. 
 
Table D6.  Mean estimated water concentrations of naproxen detected in 
Chemcatcher® passive samplers and spot samples  
Site Sample 
Sampling 
duration (d) 
Period 
SS 
Concentration [ng L
-1
] 
PS (TWA) SS 
1 RW 28 Feb/Mar 97 23 
1 TW 28 Feb/Mar n.d. n.d. 
1 RW 28 Mar/Apr 64 23 
1 TW 28 Mar/Apr n.d. n.d. 
1 RW 28 Apr/May 16 18 
1 TW 28 Apr/May n.d. n.d. 
1 RW 29 May/Jun 41 13 
1 TW 29 May/Jun n.d. n.d. 
1 RW 23 Jun 91 12 
1 TW 23 Jun n.d. n.d. 
1 RW 32 Jun/Jul 35 13 
1 TW 32 Jun/Jul n.d. n.d. 
1 RW 28 Jul/Aug 27 13 
1 TW 28 Jul/Aug n.d. n.d. 
2 RW 28 May/Jun n.d. 18
c
 
2 TW 28 May/Jun n.d. n.d. 
2 RW 32 Jun/Jul n.d. 9 
2 TW 32 Jun/Jul n.d. n.d. 
2 RW 28 Jul/Aug n.d. 9 
2 TW 28 Jul/Aug n.d. n.d. 
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APPENDIX E: CHEMCATCHER CALIBRATION DATA 
 
Table E1. Chemcatcher® calibration results   
Compound
a
 
Time 
[d] 
Water conc. 
[ng L
-1
] 
Slope 
[ng d
-1
] r
2
adj 
Lack of fit  
p 
Rs 
[ml d
-
1
] 
Atenolol 6 - 30 43.1 0.2846 32.6 0.393 7 
Benzoylecgonine 1 - 30 71.8 0.2391 58.9  0.029
b
 3 
Caffeine 2 - 30 40.3 0.2808 42.0 0.170 7 
Carbamazepine 6 - 30 139.7 0.4151  24.0
c
 0.107 3 
Cocaine  2 - 30 156.1 0.2117 34.8 0.117 1 
Diclofenac
d
 1 -  30 73.4 0.2139 26.0 <0.001 3 
Ibuprofen 1 - 30 128.3 0.8743 84.7 0.137 7 
Ketoprofen 1 - 20 152.4 1.790 89.8 0.799 12 
Naproxen 2 - 30 108.3 0.3751 52.7 0.198 6 
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APPENDIX F: FLOW DATA FOR STUDY SITES 
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Figure F1 Gauged daily flow data for closest gauging site to water abstraction point for 
site 1 during the study period. 
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Figure F2 Gauged daily flow data for closest gauging site to water abstraction point for 
site 2 during the study period. 
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Figure F3 Gauged daily flow data for closest gauging site to water abstraction point for 
site 3 during the study period. 
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Figure F4 Gauged daily flow data for closest gauging site to water abstraction point for 
site 4 (Blackwater) during the study period. 
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Figure F5 Gauged daily flow data for closest gauging site to water abstraction point for 
site 4 (Chelmer) during the study period. 
